ABEONA THERAPEUTICS INC. 8K

Abeona Therapeutics reported Q2 2026 financial results showing growing ZEVASKYN revenues, expanding treatment center network, CMS NTAP reimbursement approval, and a continued net loss with declining cash balance.

Abeona Therapeutics Inc. reported its second quarter 2026 results and business update, highlighting that net ZEVASKYN revenue grew 31% quarter-over-quarter to $11.4 million on five treated patients (with revenue recognized for four treatments due to manufacturing yield constraints), while cumulative commercial treatments reached 12 and the qualified treatment center network expanded to seven sites including NewYork-Presbyterian/Columbia, CHOP, UTMB, and Cincinnati Children’s. The company secured CMS New Technology Add-On Payment (NTAP) status for ZEVASKYN effective October 1, 2026, which is expected to support hospital adoption and Medicare patient access, and continued medical conference engagement to raise awareness in the RDEB community. Operating metrics showed reduced R&D and SG&A expenses versus Q1 2026, but Abeona reported a Q2 2026 net loss of $20.2 million ($0.35 per share) and a decline in cash, cash equivalents and short-term investments to $146.8 million as of June 30, 2026 from $191.4 million at year-end 2025. The company also disclosed updated condensed consolidated financial statements, including total assets of $179.5 million, total liabilities of $51.4 million, and stockholders’ equity of $128.1 million as of June 30, 2026, and announced details of a conference call to discuss these results and ongoing commercialization of ZEVASKYN.

Filing Facts

CIK

318306

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-037575

Alert Tier

7